CovPDB: a high-resolution coverage of the covalent protein–ligand interactome
M Gao, AFA Moumbock, A Qaseem, Q Xu… - Nucleic Acids …, 2022 - academic.oup.com
In recent years, the drug discovery paradigm has shifted toward compounds that covalently
modify disease-associated target proteins, because they tend to possess high potency …
modify disease-associated target proteins, because they tend to possess high potency …
[PDF][PDF] CovPDB: a high-resolution coverage of the covalent protein–ligand interactome
M Gao, AFA Moumbock, A Qaseem, Q Xu… - Nucleic Acids …, 2021 - researchgate.net
In recent years, the drug discovery paradigm has shifted toward compounds that covalently
modify disease-associated target proteins, because they tend to possess high potency …
modify disease-associated target proteins, because they tend to possess high potency …
[HTML][HTML] CovPDB: a high-resolution coverage of the covalent protein–ligand interactome
M Gao, AFA Moumbock, A Qaseem, Q Xu… - Nucleic Acids …, 2022 - ncbi.nlm.nih.gov
In recent years, the drug discovery paradigm has shifted toward compounds that covalently
modify disease-associated target proteins, because they tend to possess high potency …
modify disease-associated target proteins, because they tend to possess high potency …
CovPDB: a high-resolution coverage of the covalent protein-ligand interactome.
M Gao, AFA Moumbock, A Qaseem, Q Xu… - Nucleic Acids …, 2022 - europepmc.org
In recent years, the drug discovery paradigm has shifted toward compounds that covalently
modify disease-associated target proteins, because they tend to possess high potency …
modify disease-associated target proteins, because they tend to possess high potency …
CovPDB: a high-resolution coverage of the covalent protein-ligand interactome
M Gao, AFA Moumbock, A Qaseem… - Nucleic acids …, 2022 - pubmed.ncbi.nlm.nih.gov
In recent years, the drug discovery paradigm has shifted toward compounds that covalently
modify disease-associated target proteins, because they tend to possess high potency …
modify disease-associated target proteins, because they tend to possess high potency …
[PDF][PDF] CovPDB: a high-resolution coverage of the covalent protein–ligand interactome
M Gao, AFA Moumbock, A Qaseem, Q Xu, S Gunther - pdfs.semanticscholar.org
In recent years, the drug discovery paradigm has shifted toward compounds that covalently
modify disease-associated target proteins, because they tend to possess high potency …
modify disease-associated target proteins, because they tend to possess high potency …
[PDF][PDF] CovPDB: a high-resolution coverage of the covalent protein–ligand interactome
M Gao, AFA Moumbock, A Qaseem, Q Xu… - Nucleic Acids …, 2022 - academic.oup.com
In recent years, the drug discovery paradigm has shifted toward compounds that covalently
modify disease-associated target proteins, because they tend to possess high potency …
modify disease-associated target proteins, because they tend to possess high potency …
[PDF][PDF] CovPDB: A HighResolution Coverage of the Covalent Protein–Ligand Interactome
M Gao, AFA Moumbock, A Qaseem, Q Xu… - … Drug Discovery through …, 2022 - d-nb.info
Inrecent years, the drugdiscovery paradigmhas shiftedtoward compoundsthat covalently
modify diseaseassociated target proteins, because they tend to possess high potency …
modify diseaseassociated target proteins, because they tend to possess high potency …
[PDF][PDF] CovPDB: A HighResolution Coverage of the Covalent Protein–Ligand Interactome
M Gao, AFA Moumbock, A Qaseem, Q Xu… - … Discovery through the …, 2022 - researchgate.net
Inrecent years, the drugdiscovery paradigmhas shiftedtoward compoundsthat covalently
modify diseaseassociated target proteins, because they tend to possess high potency …
modify diseaseassociated target proteins, because they tend to possess high potency …